CML: The good, the better, and the difficult choices

Research output: Contribution to journalComment/debate

Abstract

In this issue of Blood, Radich and colleagues from 4 cooperative groups report on the results of a randomized study of dasatinib versus imatinib as initial treatment for patients with chronic phase chronic myeloid leukemia (CML).

Original languageEnglish (US)
Pages (from-to)3866-3867
Number of pages2
JournalBlood
Volume120
Issue number19
DOIs
StatePublished - Nov 8 2012
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Blood
Therapeutics
Imatinib Mesylate
Dasatinib

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

CML : The good, the better, and the difficult choices. / Cortes, Jorge.

In: Blood, Vol. 120, No. 19, 08.11.2012, p. 3866-3867.

Research output: Contribution to journalComment/debate

Cortes, Jorge. / CML : The good, the better, and the difficult choices. In: Blood. 2012 ; Vol. 120, No. 19. pp. 3866-3867.
@article{38e0bb22d3934b8b88a1ba28f4b6d08d,
title = "CML: The good, the better, and the difficult choices",
abstract = "In this issue of Blood, Radich and colleagues from 4 cooperative groups report on the results of a randomized study of dasatinib versus imatinib as initial treatment for patients with chronic phase chronic myeloid leukemia (CML).",
author = "Jorge Cortes",
year = "2012",
month = "11",
day = "8",
doi = "10.1182/blood-2012-09-452789",
language = "English (US)",
volume = "120",
pages = "3866--3867",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",

}

TY - JOUR

T1 - CML

T2 - The good, the better, and the difficult choices

AU - Cortes, Jorge

PY - 2012/11/8

Y1 - 2012/11/8

N2 - In this issue of Blood, Radich and colleagues from 4 cooperative groups report on the results of a randomized study of dasatinib versus imatinib as initial treatment for patients with chronic phase chronic myeloid leukemia (CML).

AB - In this issue of Blood, Radich and colleagues from 4 cooperative groups report on the results of a randomized study of dasatinib versus imatinib as initial treatment for patients with chronic phase chronic myeloid leukemia (CML).

UR - http://www.scopus.com/inward/record.url?scp=84868593987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868593987&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-09-452789

DO - 10.1182/blood-2012-09-452789

M3 - Comment/debate

C2 - 23144157

AN - SCOPUS:84868593987

VL - 120

SP - 3866

EP - 3867

JO - Blood

JF - Blood

SN - 0006-4971

IS - 19

ER -